Pemziviptadil (PB1046)

A long-acting VIP analogue to manage pulmonary arterial hypertension and improve cardiac function

We are currently conducting a Phase 2B trial in pulmonary arterial hypertension (PAH), as well as a long-term, open label extension study of pemziviptadil in PAH subjects following completion of the VIP study.

For additional information, please visit:

Raymond Benza, MD, professor of medicine at Temple University, College of Medicine and James Magovern chair of cardiovascular research at the Allegheny Health Network, shares the limitations of the current medicines we have to treat the PAH. He provides more information on PhaseBio’s clinical trial investigating pemziviptadil for the treatment of patients with PAH.

If you have a question on our clinical trials, please email clinicaltrials@phasebio.com.